CL2021000981A1 - Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361) - Google Patents

Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)

Info

Publication number
CL2021000981A1
CL2021000981A1 CL2021000981A CL2021000981A CL2021000981A1 CL 2021000981 A1 CL2021000981 A1 CL 2021000981A1 CL 2021000981 A CL2021000981 A CL 2021000981A CL 2021000981 A CL2021000981 A CL 2021000981A CL 2021000981 A1 CL2021000981 A1 CL 2021000981A1
Authority
CL
Chile
Prior art keywords
peptides
cancers
present
divisional application
peptide combinations
Prior art date
Application number
CL2021000981A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Colette Song
Harpreet Singh
Andrea Mahr
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511792.2A external-priority patent/GB201511792D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2021000981A1 publication Critical patent/CL2021000981A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invención se relaciona con péptidos, proteínas, ácidos nucleicos y células para usar en métodos inmunoterapéuticos. En particular, la presente invención se relaciona con la inmunoterapia de cáncer. La presente invención además se relaciona con epitopes peptídicos de células T asociados a tumor, solos o en combinación con otros péptidos asociados a tumor que por ejemplo pueden servir como ingredientes farmacéuticos activos de composiciones de vacuna que estimulan respuestas inmunológicas antitumorales, a para estimular a células T ex vivo y transferirlas a los pacientes. Los péptidos unidos a las moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tal, también pueden ser blancos de anticuerpos, receptores solubles de células T, y de otras moléculas de unión.
CL2021000981A 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361) CL2021000981A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188870P 2015-07-06 2015-07-06
GBGB1511792.2A GB201511792D0 (en) 2015-07-06 2015-07-06 Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers

Publications (1)

Publication Number Publication Date
CL2021000981A1 true CL2021000981A1 (es) 2021-09-10

Family

ID=56368954

Family Applications (7)

Application Number Title Priority Date Filing Date
CL2017003361A CL2017003361A1 (es) 2015-07-06 2017-12-26 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
CL2021000981A CL2021000981A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000980A CL2021000980A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000979A CL2021000979A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000982A CL2021000982A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2023000706A CL2023000706A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer
CL2023000708A CL2023000708A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017003361A CL2017003361A1 (es) 2015-07-06 2017-12-26 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres

Family Applications After (5)

Application Number Title Priority Date Filing Date
CL2021000980A CL2021000980A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000979A CL2021000979A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000982A CL2021000982A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2023000706A CL2023000706A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer
CL2023000708A CL2023000708A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer

Country Status (32)

Country Link
US (21) US10487132B2 (es)
EP (2) EP3736283A1 (es)
JP (3) JP6944382B2 (es)
KR (1) KR20180026758A (es)
CN (2) CN107912043B (es)
AU (3) AU2016289754B2 (es)
BR (1) BR112017028363A2 (es)
CA (2) CA2991396A1 (es)
CL (7) CL2017003361A1 (es)
CO (1) CO2017012886A2 (es)
CR (3) CR20230563A (es)
DK (1) DK3319985T3 (es)
EA (1) EA201792671A1 (es)
ES (1) ES2841507T3 (es)
HR (1) HRP20210076T1 (es)
HU (1) HUE052628T2 (es)
IL (2) IL313594A (es)
LT (1) LT3319985T (es)
MA (1) MA51531A (es)
MD (1) MD3319985T2 (es)
MX (2) MX2017017148A (es)
MY (2) MY198784A (es)
PE (3) PE20240778A1 (es)
PH (1) PH12018500004A1 (es)
PL (1) PL3319985T3 (es)
PT (1) PT3319985T (es)
RS (1) RS61203B1 (es)
SG (1) SG10202001668PA (es)
SI (1) SI3319985T1 (es)
TW (2) TW202222825A (es)
UA (1) UA124411C2 (es)
ZA (1) ZA201707810B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3319985T2 (ro) 2015-07-06 2021-01-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CN109628591B (zh) * 2018-12-04 2022-04-15 南方医科大学南方医院 用于肺腺癌预后预测的标志物
CN112007167B (zh) * 2020-08-29 2023-01-24 南京中医药大学 蟾酥多肽在作为蟾蜍甾烯促渗剂中的应用
CN112812197B (zh) * 2021-01-11 2022-05-31 中国药科大学 一种兰州百合多糖及其制备方法和应用
CN114057860B (zh) * 2021-11-09 2023-10-20 中国科学技术大学 特定组氨酸甲基化修饰的s100a9蛋白免疫原、多克隆抗体及其制备方法
CN114717191B (zh) * 2022-04-26 2023-06-16 兰州大学第一医院 一株人肝内胆管癌细胞株icc-x3及其应用
CN115322967B (zh) * 2022-06-13 2023-08-08 浙江省人民医院 一种永生化人甲状腺乳头状癌成纤维细胞株及其构建方法和应用
CN114957399B (zh) * 2022-06-29 2023-05-09 湖北工业大学 一种多肽、多肽衍生物及其在制备抗肿瘤药物中的应用
CN116449015A (zh) * 2022-08-26 2023-07-18 成都益安博生物技术有限公司 一种胃癌的外周血tcr标志物序列及其检测试剂盒和应用
CN116183920B (zh) * 2022-09-22 2023-10-20 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于检测鼻咽癌预后的抗体组合、系统及应用
CN116144772B (zh) * 2022-11-18 2023-08-25 昆明医科大学第一附属医院 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用
CN115737619A (zh) * 2022-11-21 2023-03-07 深圳承启生物科技有限公司 一种用于抑制肿瘤的药物靶点、用途及口服药物
CN115831228B (zh) * 2022-12-08 2025-05-16 西北工业大学 一种基于线性混合模型的基因调控网络推断方法
CN116676334B (zh) * 2023-02-08 2025-05-27 深圳大学 抑郁症动物模型的构建方法
CN117106910B (zh) * 2023-08-10 2025-03-11 杭州师范大学 外周血白细胞rna联合标志物在制备检测或诊断早期原发性胆囊癌试剂盒中的应用
CN117843721B (zh) * 2024-03-07 2024-05-10 鲁东大学 一种扇贝源抗氧化肽及其制备方法与应用
CN119307618B (zh) * 2024-12-13 2025-03-14 浙江大学医学院附属邵逸夫医院 肝内胆管癌发生与发展过程中的关键分子的创新筛选方法及应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
EP0916678A3 (en) 1993-06-03 1999-05-26 Therapeutic Antibodies Inc. Method of clotting blood
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2000039297A2 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
AU7103198A (en) * 1997-04-21 1998-11-13 Schering Corporation Mammalian cytokines; related reagents and methods
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
CA2393662A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
ATE472601T1 (de) 2000-03-27 2010-07-15 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1289564B1 (en) 2000-06-05 2018-07-18 Altor BioScience Corporation T cell receptor fusions and conjugates and methods of use thereof
JP2004517609A (ja) * 2000-09-01 2004-06-17 エピミューン インコーポレイテッド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP2295602B1 (en) * 2005-07-27 2012-07-11 Oncotherapy Science, Inc. Method of prognosing cancers
PL1806358T3 (pl) 2005-09-05 2010-08-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
ES2330013T3 (es) 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
US20100129928A1 (en) * 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
US8034771B2 (en) * 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
UA103751C2 (ru) 2007-07-27 2013-11-25 Имматикс Биотекнолоджис Гмбх Иммуногенный пептид для иммунотерапии
BRPI0813621A2 (pt) 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010120554A1 (en) * 2009-04-01 2010-10-21 The Regents Of The University Of California Detecting and treating breast cancer resistance to egfr inhibitors
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US20120225954A1 (en) 2010-09-05 2012-09-06 University Health Network Methods and compositions for the classification of non-small cell lung carcinoma
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
JP2015226468A (ja) 2012-08-27 2015-12-17 北海道公立大学法人 札幌医科大学 ｐ５３ファミリーキメラ分子およびその使用
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MD3319985T2 (ro) 2015-07-06 2021-01-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架

Also Published As

Publication number Publication date
AU2022205209A1 (en) 2022-08-04
US20220106380A1 (en) 2022-04-07
MX2017017148A (es) 2018-02-23
PT3319985T (pt) 2021-01-06
CL2017003361A1 (es) 2018-05-04
CN107912043B (zh) 2022-02-18
IL313594A (en) 2024-08-01
US20220119486A1 (en) 2022-04-21
US20190315832A1 (en) 2019-10-17
CA2991396A1 (en) 2017-01-12
MA51531A (fr) 2020-11-11
US10487132B2 (en) 2019-11-26
MD3319985T2 (ro) 2021-01-31
US20200157176A1 (en) 2020-05-21
ZA201707810B (en) 2018-11-28
AU2016289754B2 (en) 2021-02-18
AU2021200800A1 (en) 2021-03-04
US12351616B2 (en) 2025-07-08
US10626162B2 (en) 2020-04-21
HUE052628T2 (hu) 2021-05-28
CL2021000980A1 (es) 2021-09-10
EP4321172A2 (en) 2024-02-14
CL2021000979A1 (es) 2021-09-10
US20210024609A1 (en) 2021-01-28
TW202222825A (zh) 2022-06-16
HK1255542A1 (en) 2019-08-23
HRP20210076T1 (hr) 2021-05-14
TWI776332B (zh) 2022-09-01
PE20240778A1 (es) 2024-04-17
BR112017028363A2 (pt) 2018-08-28
EP3736283A1 (en) 2020-11-11
US11359003B2 (en) 2022-06-14
CR20230563A (es) 2024-01-22
US11932678B2 (en) 2024-03-19
AU2022205209B2 (en) 2024-05-09
US10703795B2 (en) 2020-07-07
PE20231014A1 (es) 2023-07-05
US12297254B2 (en) 2025-05-13
JP2022020614A (ja) 2022-02-01
CL2021000982A1 (es) 2021-09-10
JP6944382B2 (ja) 2021-10-06
LT3319985T (lt) 2020-12-28
US20220098277A1 (en) 2022-03-31
US20210277086A1 (en) 2021-09-09
US20220098275A1 (en) 2022-03-31
AU2016289754A1 (en) 2017-11-30
US20200291088A1 (en) 2020-09-17
SI3319985T1 (sl) 2021-01-29
US20220135648A1 (en) 2022-05-05
CN113880938A (zh) 2022-01-04
CL2023000708A1 (es) 2023-08-18
JP2024041841A (ja) 2024-03-27
US20200010531A1 (en) 2020-01-09
US20220119487A1 (en) 2022-04-21
US20220135647A1 (en) 2022-05-05
CR20230562A (es) 2024-01-22
IL256303B2 (en) 2025-02-01
US20220119485A1 (en) 2022-04-21
JP2018519825A (ja) 2018-07-26
CR20170579A (es) 2018-05-25
US20220135646A1 (en) 2022-05-05
KR20180026758A (ko) 2018-03-13
PE20180259A1 (es) 2018-02-05
AU2021200800B2 (en) 2022-08-18
DK3319985T3 (da) 2021-01-04
IL256303A (en) 2018-02-28
ES2841507T3 (es) 2021-07-08
US20220098276A1 (en) 2022-03-31
MX2021013003A (es) 2022-01-18
US20220106379A1 (en) 2022-04-07
MY188354A (en) 2021-12-02
EP4321172A3 (en) 2024-08-21
US12258382B2 (en) 2025-03-25
RS61203B1 (sr) 2021-01-29
US11608370B2 (en) 2023-03-21
TW202124430A (zh) 2021-07-01
US11401319B2 (en) 2022-08-02
US20220112266A1 (en) 2022-04-14
PH12018500004A1 (en) 2018-07-09
PL3319985T3 (pl) 2021-05-04
US11939366B2 (en) 2024-03-26
CN107912043A (zh) 2018-04-13
CO2017012886A2 (es) 2018-03-09
UA124411C2 (uk) 2021-09-15
US10829537B2 (en) 2020-11-10
US20210277087A1 (en) 2021-09-09
US20220119484A1 (en) 2022-04-21
CL2023000706A1 (es) 2023-08-18
CN113880938B (zh) 2025-09-05
US11999774B2 (en) 2024-06-04
MY198784A (en) 2023-09-27
SG10202001668PA (en) 2020-04-29
IL256303B1 (en) 2024-10-01
EA201792671A1 (ru) 2018-06-29
US20210277088A1 (en) 2021-09-09
CA3221001A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
CL2021000979A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
MX2018005273A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer.
MX2018001421A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer.
MX2018005374A (es) Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer.
CO2017009616A2 (es) Péptidos y combinación de péptidos y andamiajes para inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
MX2018005372A (es) Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra la leucemia linfocitica cronica (cll) y otros tipos de cancer.
MX2018004140A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer.
MX2017012427A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
MX2017017145A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
MX2018002480A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
CR20210234A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
MX2017016207A (es) Epitopos celulares novedosos y combinacion de epitopos celulares para usarse en la inmunoterapia de mieloma y otros canceres.
MX2018011215A (es) Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pulmon amicrocitico y otros tipos de cancer.
PE20230768A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon amicrocitico y otros tipos de cancer
CR20190388A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CO2018000245A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
MX2018011388A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
CR20220115A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
CL2024000530A1 (es) Péptidos y combinaciones, su uso en la inmunoterapia contra cáncer de pulmón y otros cánceres
MX2019012226A (es) Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer.
MX2018012758A (es) Inmunoterapia contra el melanoma y otros tipos de cancer.
CL2023001324A1 (es) Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres
CR20210232A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
CO2017003772A2 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
AR124242A2 (es) Péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres